- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166
MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the …
MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
As quoted in the press release:
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover a method of treating a patient diagnosed with ALS, as well as a wide range of other neurodegenerative diseases, with the combination of MN-166 (ibudilast) and riluzole. Other neurodegenerative diseases covered by this patent include Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, Lewy body disease, motor neuron disease, spinal muscular atrophy, myelopathy, traumatic brain injury, spinal cord injury, and many others.
MediciNova was previously granted a U.S. patent which covers the use of MN-166 (ibudilast) as monotherapy for the treatment of amyotrophic lateral sclerosis (ALS) and it expires no earlier than January 2029. MediciNova was previously granted three U.S. patents which cover the use of MN-166 (ibudilast) as monotherapy for the treatment of progressive multiple sclerosis including both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.  The first one of these patents expires no earlier than November 2029 and patent term restoration would add 5 years once MN-166 (ibudilast) is approved for progressive multiple sclerosis, extending the patent expiration to November 2034.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â